1House AK, Potter JM,Smith PA, et al. Heparinization in aortic surgery[ J]. J Cardiovase Surg(Torino), 1988,29(6) :707-711.
2Granger CB, Hirsch J, Califf RM, et al. Activated partial thromboplasin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-1 trial[J]. Circulation, 1996,93(5) :870-878.
3Reddan D, Szczech LA, O'Shea S, et al. Anticoagulation in acute cardiac care in patientes with chronic kidney disease[ J]. Am Heart J, 2003,145(4) :586-594.
4Weitz JI, Buller HR. Direct thrombin inhibitors in acute coronary syndromes: present and future[J]. Circulation .2002.105(8) : 1004-1011.
5Kooistra MP, Van Es A, Mark JJ, et al. Low-dose aspirin dose not prevent thrombovascular accidents in low-risk hemodialysis patients during treatment with recombinant human erythropoietin [ J ]. Nephrol Dial Trans Plant, 1994,9(8) : 1115-1120.
6Vaitkus PT. Current status of prevention,diagnosis and management of coronary artery disease in patients with kidney failure[J]. Am Heart J,2000,139(6) : 1000-1008.
7Kimak E, Solski J. apoA-and apoB-eontaining lipoproteins and Lp (a) concenteation in non-dialyzed patients with chronic renal failure [ J].Ren Fail,2002,24(4) :485-492.
8Zidek W. Homocysteine-a new arteriosclerotic risk factor in end-stagerenal failure[ J]. Nephron, 1997,75(3) :249-250.
9Thompson CH, Irish A, Kemp GJ, et al. Skeletal muscle metabolism before and after gemfihmzil treatment in dialysed patients with chronic renal failure[J] .Clin Nephml, 1996,45(6):386-389.
10Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phaseⅢ muhicenter clinical trial[J] .Ann Intern Med, 1989, 111(12) :992-1000.
